MA31800B1 - Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique - Google Patents

Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique

Info

Publication number
MA31800B1
MA31800B1 MA32806A MA32806A MA31800B1 MA 31800 B1 MA31800 B1 MA 31800B1 MA 32806 A MA32806 A MA 32806A MA 32806 A MA32806 A MA 32806A MA 31800 B1 MA31800 B1 MA 31800B1
Authority
MA
Morocco
Prior art keywords
ptsd
treatment
tetrahydroquinoline derivatives
derivatives
group
Prior art date
Application number
MA32806A
Other languages
Arabic (ar)
English (en)
Inventor
François Jenck
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31800(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31800B1 publication Critical patent/MA31800B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de dérivés de tétrahydroquinoléine représentés par la formule (i), r1 et r2 représentant chacun indépendamment un groupe alcoxy en c1-c4, r3 représentant un groupe arylalkyle en c1-c4 ou hétéroarylalkyle en c1-c4, et r4 représentant un atome d'hydrogène ou un groupe alkyle en c1-c4, ou de sels pharmaceutiquement acceptables de ces dérivés, pour la préparation d'un médicament destiné à prévenir ou traiter des troubles de stress post-traumatique.
MA32806A 2007-10-10 2010-04-30 Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique MA31800B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (fr) 2007-10-10 2008-10-09 Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique

Publications (1)

Publication Number Publication Date
MA31800B1 true MA31800B1 (fr) 2010-10-01

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32806A MA31800B1 (fr) 2007-10-10 2010-04-30 Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique

Country Status (28)

Country Link
US (1) US9532985B2 (fr)
EP (1) EP2207550B1 (fr)
JP (1) JP5883222B2 (fr)
KR (1) KR101733247B1 (fr)
CN (1) CN101820878B (fr)
AR (1) AR068768A1 (fr)
AU (1) AU2008309194B2 (fr)
BR (1) BRPI0818617A2 (fr)
CA (1) CA2699504C (fr)
CY (1) CY1114799T1 (fr)
DK (1) DK2207550T3 (fr)
EA (1) EA017443B1 (fr)
ES (1) ES2444418T3 (fr)
HK (1) HK1145440A1 (fr)
HR (1) HRP20140214T1 (fr)
IL (1) IL204838A (fr)
MA (1) MA31800B1 (fr)
MX (1) MX2010003711A (fr)
MY (1) MY153044A (fr)
NZ (1) NZ585086A (fr)
PE (1) PE20091010A1 (fr)
PL (1) PL2207550T3 (fr)
PT (1) PT2207550E (fr)
SI (1) SI2207550T1 (fr)
TW (1) TWI428129B (fr)
UA (1) UA99150C2 (fr)
WO (1) WO2009047723A2 (fr)
ZA (1) ZA201003251B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007337659A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US20110105514A1 (en) 2008-06-25 2011-05-05 Hamed Aissaoui 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
EP2402322A1 (fr) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. Dérivé de 1,2,3,4-tétrahydroisoquinoline et son utilisation comme antagoniste du récepteur de l'orexine
TW201209037A (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
PE20131162A1 (es) 2010-09-22 2013-10-19 Eisai Randd Man Co Ltd Compuestos de ciclopropano como antagonistas del receptor de orexina
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
WO2012085857A1 (fr) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-ylamides
EP2675801B1 (fr) 2011-02-18 2015-04-08 Actelion Pharmaceuticals Ltd. Nouveaux dérivés de pyrazole et d'imidazole utiles à titre d'antagonistes d'orexine
WO2012114252A1 (fr) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Nouveaux amides d'indole et de pyrrolopyridine
WO2013050938A1 (fr) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd Dérivés de 3,7-diazabicyclo[3.3.1]nonane et de 9-oxa-3,7- diazabicyclo[3.3.1]nonane
IN2014CN04127A (fr) 2011-11-08 2015-07-10 Actelion Pharmaceuticals Ltd
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
SG11201502493XA (en) 2012-10-10 2015-04-29 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
JP2016510810A (ja) 2013-03-12 2016-04-11 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体
HUE035731T2 (hu) 2013-12-03 2018-05-28 Idorsia Pharmaceuticals Ltd (S)-(2-(6-klór-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2- (2H-l,2,3-triazol-2-il)fenil)metanon kristályos formája és alkalmazása orexin receptor antagonistaként
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
TR201815342T4 (tr) 2013-12-04 2018-11-21 Idorsia Pharmaceuticals Ltd Benzimidazol-prolin türevlerinin kullanımı.
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
WO2019024845A1 (fr) * 2017-08-01 2019-02-07 苏州科睿思制药有限公司 Forme cristalline d'antagoniste du récepteur de l'orexine, procédé de préparation associé et utilisation correspondante
WO2020007964A1 (fr) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 2-(2-azabicyclo [3.1.0] hexan-1-yl)-1h-benzimidazole
WO2020007977A1 (fr) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 7-trifluorométhyl-[1,4]diazépane
WO2020099511A1 (fr) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Dérivés de benzimidazole-2-méthyl-morpholine
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4009460B2 (ja) * 2000-03-14 2007-11-14 アクテリオン ファマシューティカルズ リミテッド 1,2,3,4−テトラヒドロイソキノリン誘導体
CN100432056C (zh) * 2003-03-26 2008-11-12 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
WO2005118548A1 (fr) * 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Derives de 1,2,3,4-tétrahydroisoquinoléine substitués
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
MX2008011647A (es) * 2006-03-15 2008-09-22 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolina para mejorar la funcion de la memoria.
EP2402322A1 (fr) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. Dérivé de 1,2,3,4-tétrahydroisoquinoline et son utilisation comme antagoniste du récepteur de l'orexine

Also Published As

Publication number Publication date
CN101820878A (zh) 2010-09-01
TWI428129B (zh) 2014-03-01
EA201000557A1 (ru) 2010-10-29
CA2699504A1 (fr) 2009-04-16
CN101820878B (zh) 2012-02-01
KR101733247B1 (ko) 2017-05-08
IL204838A0 (en) 2010-11-30
EA017443B1 (ru) 2012-12-28
SI2207550T1 (sl) 2014-03-31
PT2207550E (pt) 2014-02-07
AU2008309194A1 (en) 2009-04-16
JP5883222B2 (ja) 2016-03-09
WO2009047723A2 (fr) 2009-04-16
KR20100065203A (ko) 2010-06-15
EP2207550B1 (fr) 2013-12-11
UA99150C2 (ru) 2012-07-25
WO2009047723A3 (fr) 2009-05-28
CY1114799T1 (el) 2016-12-14
TW200932231A (en) 2009-08-01
DK2207550T3 (da) 2014-01-27
PL2207550T3 (pl) 2014-05-30
ZA201003251B (en) 2011-07-27
HK1145440A1 (en) 2011-04-21
NZ585086A (en) 2012-03-30
MX2010003711A (es) 2010-04-30
BRPI0818617A2 (pt) 2015-04-07
US20100234420A1 (en) 2010-09-16
CA2699504C (fr) 2015-11-24
HRP20140214T1 (hr) 2014-04-11
PE20091010A1 (es) 2009-08-08
MY153044A (en) 2014-12-31
JP2011500550A (ja) 2011-01-06
ES2444418T3 (es) 2014-02-25
EP2207550A2 (fr) 2010-07-21
US9532985B2 (en) 2017-01-03
IL204838A (en) 2014-09-30
AR068768A1 (es) 2009-12-02
AU2008309194B2 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
MA31800B1 (fr) Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique
TNSN07178A1 (fr) N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues
MA31373B1 (fr) Composes amino-heterocycliques
MA28747B1 (fr) Dérivés de pyridine
MA26875A1 (fr) Composes azapolycycliques a noyau aryle condensé
TNSN04137A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
MA31988B1 (fr) Derives d'aminopyrazole
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
WO2005012269A8 (fr) Nouveau compose azole
MA27735A1 (fr) Heterocycles de n-aryle substitues, procede pour leur preparation et leur utilisation en tant que medicaments
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
SE0104334D0 (sv) Therapeutic agents
HK1077567A1 (en) Dibenzylamine compound and medicinal use thereof
TN2009000450A1 (fr) Derives de pyridine
MA31146B1 (fr) Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisation
MA34450B1 (fr) Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique
MA29926B1 (fr) Derives de pyrazine
WO2002008219A3 (fr) Nouvelles 2-adamantylethylamines et leur utilisation dans le traitement d'etats generalement associes a des anomalies de la transmission glutamatergique
MA30420B1 (fr) Derives de terphenyle pour le traitment de la maladie d'alzheimer
DE60130119D1 (de) Phenylpyridazinderivate und diese enthaltende arzneimittel
NO20072643L (no) Fenylpiperazinmethanonderivater
MY146599A (en) New azetidine compounds
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique